Related Experiment Videos
Sustained-release naltrexone for alcoholism treatment: a preliminary study
H R Kranzler1, V Modesto-Lowe, E S Nuwayser
1Alcohol Research Center, Department of Psychiatry, University of Connecticut Health Center, Farmington 06030-2103, USA.
Alcoholism, Clinical and Experimental Research
|September 3, 1998
Summary
Injectable naltrexone (NTX) showed promise for alcohol dependence treatment. This sustained-release preparation (SRP) of NTX reduced heavy drinking days and was well-tolerated.
Area of Science:
- Pharmacology and Addiction Medicine
Background:
- Alcohol dependence is a significant public health issue requiring effective treatment options.
- Oral naltrexone (NTX) is approved for alcohol dependence but adherence can be challenging.
Purpose of the Study:
- To evaluate the bioavailability, tolerability, and efficacy of an injectable sustained-release preparation (SRP) of naltrexone (NTX).
- To assess the potential of SRP-NTX as a novel treatment for alcohol dependence.
Main Methods:
- A 12-week study involving 20 alcohol-dependent subjects.
- Subjects initially received oral NTX, followed by a washout period.
- Participants then received a single subcutaneous injection of SRP-NTX (206 mg) or placebo, alongside weekly coping skills sessions.
Main Results:
- Naltrexone plasma concentrations remained above 1 ng/ml for 21 days post-injection.
- Adverse effects of SRP-NTX were comparable to oral NTX.
- SRP-NTX significantly reduced heavy drinking days compared to placebo during the injection and follow-up periods.
Conclusions:
- The injectable sustained-release preparation of naltrexone demonstrates potential clinical utility.
- SRP-NTX may offer a valuable alternative for managing alcohol dependence, potentially improving treatment adherence.